Disclosed are a novel head-and-neck tumor proliferation inhibitor, a novel head-and-neck tumor metastasis inhibitor, and a novel pharmaceutical composition for treating the head and the neck. The inhibitors and the pharmaceutical composition are characterized by utilizing an inhibitor of micro RNA of which the expression is increased in head-and-neck tumor and/or a promoter of micro RNA of which the expression is decreased in head-and-neck tumor. Preferred examples of micro RNA of which the expression is increased in head-and-neck tumor include miR-455-3p, miR-455-5p, miR-130b, miR-130b*, miR-801, miR-196a, miR-21 and miR-31. Preferred examples of micro RNA of which the expression is decreased in head-and-neck tumor include miR-133b, miR-145 and miR-375.
展开▼
